Conventional therapeutic approaches exhibit limited efficacy in controlling malignant serous cavity effusion.Therefore,there is a need to explore effective pharmacological interventions for malignant serous cavity effusion to manage disease progression and enhance patients'quality of life.The advent of Bevacizumab offers a new ray of hope in the treatment of malignant serous cavity effusion.This article systematically reviews the efficacy and safety of Bevacizumab as monotherapy or in combination for malignant pleural effusion,malignant abdominal effusion,and malignant pericardial effusion.It elucidates the mechanisms underlying the forma-tion of malignant serous cavity effusion and the role of vascular endothelial growth factors.In summary,Bevacizumab,as a targeted vascular endothelial growth factor therapy,demonstrates notable effectiveness in the treatment of malignant pleural,abdominal,and pericardial effusions.It not only improves patients'quality of life,but also mitigates adverse reactions associated with chemotherapy.Nevertheless,certain limitations persist,such as the lack of large-scale clinical studies,the absence of standardized protocols for Bevacizumab in treating malignant abdominal effusion and pericardial effusion,and a scarcity of research on Bevacizum-ab in the context of malignant pericardial effusion.
维普
万方数据